Biological and clinical heterogeneity of MYCN-amplified medulloblastoma (original) (raw)

References

  1. Aldosari N, Bigner SH, Burger PC, Becker L, Kepner JL, Friedman HS, McLendon RE (2002) MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children’s Oncology Group. Arch Pathol Lab Med 126(5):540–544
    PubMed Google Scholar
  2. Beauchamp EM, Ringer L, Bulut G, Sajwan KP, Hall MD, Lee YC, Peaceman D, Ozdemirli M, Rodriguez O, Macdonald TJ, Albanese C, Toretsky JA, Uren A (2011) Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest 121(1):148–160. doi:10.1172/JCI4287442874
    Article PubMed CAS Google Scholar
  3. Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, Watkins DN, Chen JK, Cooper MK, Taipale J, Olson JM, Beachy PA (2002) Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 297(5586):1559–1561. doi:10.1126/science.1073733297/5586/1559
    Article PubMed CAS Google Scholar
  4. Bown N, Cotterill S, Łastowska M, O’Neill S, Pearson ADJ, Plantaz D, Meddeb M, Danglot G, Brinkschmidt C, Christiansen H, Laureys G, Nicholson J, Bernheim A, Betts DR, Vandesompele J, Van Roy N, Speleman F (1999) Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 340(25):1954–1961. doi:10.1056/NEJM199906243402504
    Article PubMed CAS Google Scholar
  5. Brunet JP, Tamayo P, Golub TR, Mesirov JP (2004) Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci USA 101(12):4164–4169. doi:10.1073/pnas.03085311010308531101
    Article PubMed CAS Google Scholar
  6. Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, Berhoukim R, Amani V, Goumnerova L, Eberhart CG, Lau CC, Olson JM, Gilbertson RJ, Gajjar A, Delattre O, Kool M, Ligon K, Meyerson M, Mesirov JP, Pomeroy SL (2011) Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 29(11):1424–1430. doi:10.1200/JCO.2010.28.5148
    Article PubMed Google Scholar
  7. Eberhart CG, Kratz J, Wang Y, Summers K, Stearns D, Cohen K, Dang CV, Burger PC (2004) Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 63(5):441–449
    PubMed CAS Google Scholar
  8. Eberhart CG, Kratz JE, Schuster A, Goldthwaite P, Cohen KJ, Perlman EJ, Burger PC (2002) Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. Brain Pathol 12(1):36–44
    Article PubMed CAS Google Scholar
  9. Ellison D (2002) Classifying the medulloblastoma: insights from morphology and molecular genetics. Neuropathol Appl Neurobiol 28(4):257–282. doi:10.1046/j.1365-2990.2002.00419.x
    Article PubMed CAS Google Scholar
  10. Ellison DW (2010) Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease. Acta Neuropathol 120(3):305–316. doi:10.1007/s00401-010-0726-6
    Article PubMed Google Scholar
  11. Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G, Kenney AM, Brat DJ, Perry A, Yong WH, Taylor RE, Bailey S, Clifford SC, Gilbertson RJ (2011) Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol 121(3):381–396. doi:10.1007/s00401-011-0800-8
    Article PubMed CAS Google Scholar
  12. Ellison DW, Kocak M, Dalton J, Megahed H, Lusher ME, Ryan SL, Zhao W, Nicholson SL, Taylor RE, Bailey S, Clifford SC (2011) Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 29(11):1400–1407. doi:10.1200/JCO.2010.30.2810
    Article PubMed Google Scholar
  13. Gajjar A, Hernan R, Kocak M, Fuller C, Lee Y, McKinnon PJ, Wallace D, Lau C, Chintagumpala M, Ashley DM, Kellie SJ, Kun L, Gilbertson RJ (2004) Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 22(6):984–993. doi:10.1200/JCO.2004.06.032
    Article PubMed CAS Google Scholar
  14. Goeman JJ, le Cessie S (2006) A goodness-of-fit test for multinomial logistic regression. Biometrics 62(4):980–985. doi:10.1111/j.1541-0420.2006.00581.x
    Article PubMed Google Scholar
  15. Graf E, Schmoor C, Sauerbrei W, Schumacher M (1999) Assessment and comparison of prognostic classification schemes for survival data. Stat Med 18(17–18):2529–2545. doi:10.1002/(SICI)1097-0258(19990915/30)18:17/18<2529
    Article PubMed CAS Google Scholar
  16. Grotzer MA, von Hoff K, von Bueren AO, Shalaby T, Hartmann W, Warmuth-Metz M, Emser A, Kortmann RD, Kuehl J, Pietsch T, Rutkowski S (2007) Which clinical and biological tumor markers proved predictive in the prospective multicenter trial HIT’91–implications for investigating childhood medulloblastoma. Klin Padiatr 219(6):312–317. doi:10.1055/s-2007-985843
    Article PubMed CAS Google Scholar
  17. Katoh Y, Katoh M (2009) Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr Mol Med 9(7):873–886
    Article PubMed CAS Google Scholar
  18. Kenney AM, Cole MD, Rowitch DH (2003) Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors. Development 130(1):15–28
    Article PubMed CAS Google Scholar
  19. Kessler JD, Hasegawa H, Brun SN, Emmenegger BA, Yang ZJ, Dutton JW, Wang F, Wechsler-Reya RJ (2009) N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma. Genes Dev 23(2):157–170. doi:10.1101/gad.1759909
    Article PubMed CAS Google Scholar
  20. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, Troost D, Meeteren NS, Caron HN, Cloos J, Mrsic A, Ylstra B, Grajkowska W, Hartmann W, Pietsch T, Ellison D, Clifford SC, Versteeg R (2008) Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 3(8):e3088. doi:10.1371/journal.pone.0003088
    Article PubMed Google Scholar
  21. Korshunov A, Benner A, Remke M, Lichter P, von Deimling A, Pfister S (2008) Accumulation of genomic aberrations during clinical progression of medulloblastoma. Acta Neuropathol 116(4):383–390. doi:10.1007/s00401-008-0422-y
    Article PubMed CAS Google Scholar
  22. Korshunov A, Remke M, Werft W, Benner A, Ryzhova M, Witt H, Sturm D, Wittmann A, Schottler A, Felsberg J, Reifenberger G, Rutkowski S, Scheurlen W, Kulozik AE, von Deimling A, Lichter P, Pfister SM (2010) Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol 28(18):3054–3060. doi:10.1200/JCO.2009.25.7121
    Article PubMed Google Scholar
  23. Lamont JM, McManamy CS, Pearson AD, Clifford SC, Ellison DW (2004) Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 10(16):5482–5493. doi:10.1158/1078-0432.CCR-03-072110/16/5482
    Article PubMed CAS Google Scholar
  24. Li T, Ding C (2006) The relationships among various nonnegative matrix factorization methods for clustering. Paper presented at the Proceedings of Sixth International Conference on Data Mining
  25. Low JA, de Sauvage FJ (2010) Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol 28(36):5321–5326. doi:10.1200/JCO.2010.27.9943
    Article PubMed CAS Google Scholar
  26. Margolin AA, Nemenman I, Basso K, Wiggins C, Stolovitzky G, Dalla Favera R, Califano A (2006) ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinformatics 7(Suppl 1):S7. doi:10.1186/1471-2105-7-S1-S7
    Article PubMed Google Scholar
  27. Margolin AA, Wang K, Lim WK, Kustagi M, Nemenman I, Califano A (2006) Reverse engineering cellular networks. Nat Protoc 1(2):662–671. doi:10.1038/nprot.2006.106
    Article PubMed CAS Google Scholar
  28. Murphy DM, Buckley PG, Bryan K, Watters KM, Koster J, van Sluis P, Molenaar J, Versteeg R, Stallings RL (2011) Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis. Mol Carcinog 50(6):403–411. doi:10.1002/mc.20722
    Google Scholar
  29. Northcott PA, Fernandez LA, Hagan JP, Ellison DW, Grajkowska W, Gillespie Y, Grundy R, Van Meter T, Rutka JT, Croce CM, Kenney AM, Taylor MD (2009) The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res 69(8):3249–3255. doi:10.1158/0008-5472.CAN-08-4710
    Article PubMed CAS Google Scholar
  30. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, Rutka JT, Pfister S, Taylor MD (2011) Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29(11):1408–1414. doi:10.1200/JCO.2009.27.4324
    Article PubMed Google Scholar
  31. Northcott PA, Rutka JT, Taylor MD (2010) Genomics of medulloblastoma: from Giemsa-banding to next-generation sequencing in 20 years. Neurosurg Focus 28(1):E6. doi:10.3171/2009.10.FOCUS09218
    Article PubMed Google Scholar
  32. Oliver TG, Grasfeder LL, Carroll AL, Kaiser C, Gillingham CL, Lin SM, Wickramasinghe R, Scott MP, Wechsler-Reya RJ (2003) Transcriptional profiling of the Sonic hedgehog response: a critical role for N-myc in proliferation of neuronal precursors. Proc Natl Acad Sci USA 100(12):7331–7336. doi:10.1073/pnas.08323171000832317100
    Article PubMed CAS Google Scholar
  33. Pession A, Tonelli R (2005) The MYCN oncogene as a specific and selective drug target for peripheral and central nervous system tumors. Curr Cancer Drug Targets 5(4):273–283
    Article PubMed CAS Google Scholar
  34. Pfaff E, Remke M, Sturm D, Benner A, Witt H, Milde T, von Bueren AO, Wittmann A, Schottler A, Jorch N, Graf N, Kulozik AE, Witt O, Scheurlen W, von Deimling A, Rutkowski S, Taylor MD, Tabori U, Lichter P, Korshunov A, Pfister SM (2010) TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol 28(35):5188–5196. doi:10.1200/JCO.2010.31.1670
    Article PubMed CAS Google Scholar
  35. Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, Wittmann A, Devens F, Gerber NU, Joos S, Kulozik A, Reifenberger G, Rutkowski S, Wiestler OD, Radlwimmer B, Scheurlen W, Lichter P, Korshunov A (2009) Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 27(10):1627–1636. doi:10.1200/JCO.2008.17.9432
    Article PubMed Google Scholar
  36. Pfister SM, Korshunov A, Kool M, Hasselblatt M, Eberhart C, Taylor MD (2010) Molecular diagnostics of CNS embryonal tumors. Acta Neuropathol 120(5):553–566. doi:10.1007/s00401-010-0751-5
    Article PubMed CAS Google Scholar
  37. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran T, Wetmore C, Biegel JA, Poggio T, Mukherjee S, Rifkin R, Califano A, Stolovitzky G, Louis DN, Mesirov JP, Lander ES, Golub TR (2002) Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415(6870):436–442. doi:10.1038/415436a
    Article PubMed CAS Google Scholar
  38. Qi Q, Zhao Y, Li M, Simon R (2009) Non-negative matrix factorization of gene expression profiles: a plug-in for BRB-ArrayTools. Bioinformatics 25(4):545–547. doi:10.1093/bioinformatics/btp009
    Article PubMed CAS Google Scholar
  39. Remke M, Hielscher T, Korshunov A, Northcott PA, Bender S, Kool M, Westermann F, Benner A, Cin H, Ryzhova M, Sturm D, Witt H, Haag D, Toedt G, Wittmann A, Schottler A, von Bueren AO, von Deimling A, Rutkowski S, Scheurlen W, Kulozik AE, Taylor MD, Lichter P, Pfister SM (2011) FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J Clin Oncol 29(29):3852–3861. doi:10.1200/JCO.2011.36.2798
    Article PubMed CAS Google Scholar
  40. Remke M, Hielscher T, Northcott PA, Witt H, Ryzhova M, Wittmann A, Benner A, von Deimling A, Scheurlen W, Perry A, Croul S, Kulozik AE, Lichter P, Taylor MD, Pfister SM, Korshunov A (2011) Adult medulloblastoma comprises three major molecular variants. J Clin Oncol 29(19):2717–2723. doi:10.1200/JCO.2011.34.9373
    Article PubMed Google Scholar
  41. Rutkowski S, von Bueren A, von Hoff K, Hartmann W, Shalaby T, Deinlein F, Warmuth-Metz M, Soerensen N, Emser A, Bode U, Mittler U, Urban C, Benesch M, Kortmann RD, Schlegel PG, Kuehl J, Pietsch T, Grotzer M (2007) Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT’91. Clin Cancer Res 13(9):2651–2657. doi:10.1158/1078-0432.CCR-06-1779
    Article PubMed CAS Google Scholar
  42. Schwab M, Westermann F, Hero B, Berthold F (2003) Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 4(8):472–480 (S1470204503011665[pii])
    Article PubMed CAS Google Scholar
  43. Scott DK, Straughton D, Cole M, Bailey S, Ellison DW, Clifford SC (2006) Identification and analysis of tumor suppressor loci at chromosome 10q23.3-10q25.3 in medulloblastoma. Cell Cycle 5(20):2381–2389 (3360[pii])
    Article PubMed CAS Google Scholar
  44. Suzuki R, Shimodaira H (2006) Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics 22(12):1540–1542. doi:10.1093/bioinformatics/btl117
    Article PubMed CAS Google Scholar
  45. Swartling FJ, Grimmer MR, Hackett CS, Northcott PA, Fan QW, Goldenberg DD, Lau J, Masic S, Nguyen K, Yakovenko S, Zhe XN, Gilmer HC, Collins R, Nagaoka M, Phillips JJ, Jenkins RB, Tihan T, Vandenberg SR, James CD, Tanaka K, Taylor MD, Weiss WA, Chesler L (2010) Pleiotropic role for MYCN in medulloblastoma. Genes Dev 24(10):1059–1072. doi:10.1101/gad.1907510
    Article PubMed CAS Google Scholar
  46. Taylor RE, Bailey CC, Robinson KJ, Weston CL, Walker DA, Ellison D, Ironside J, Pizer BL, Lashford LS (2005) Outcome for patients with metastatic (M2–3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur J Cancer 41(5):727–734. doi:10.1016/j.ejca.2004.12.017
    Article PubMed CAS Google Scholar
  47. Westermann F, Muth D, Benner A, Bauer T, Henrich KO, Oberthuer A, Brors B, Beissbarth T, Vandesompele J, Pattyn F, Hero B, Konig R, Fischer M, Schwab M (2008) Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol 9(10):R150. doi:10.1186/gb-2008-9-10-r150
    Article PubMed Google Scholar
  48. Zitterbart K, Filkova H, Tomasikova L, Necesalova E, Zambo I, Kantorova D, Slamova I, Vranova V, Zezulkova D, Pesakova M, Pavelka Z, Veselska R, Kuglik P, Sterba J (2010) Low-level copy number changes of MYC genes have a prognostic impact in medulloblastoma. J Neurooncol 102:25–33. doi:10.1007/s11060-010-0289-3
    Article PubMed Google Scholar

Download references